stockportfolio.pro
Vertex Pharmaceuticals Incorporated P/E Ratio 2008–2025
Vertex Pharmaceuticals Incorporated (VRTX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -11.5%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 29.59 | — |
| FY 2024 | — | — |
| FY 2023 | 29.29 | +30.0% |
| FY 2022 | 22.53 | -7.6% |
| FY 2021 | 24.37 | +6.1% |
| FY 2020 | 22.97 | -52.7% |
| FY 2019 | 48.55 | +137.0% |
| FY 2018 | 20.48 | -85.8% |
| FY 2017 | 144.10 | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | 237.21 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
Source: Vertex Pharmaceuticals Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Vertex Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVertex Pharmaceuticals Incorporated — frequently asked questions
What is Vertex Pharmaceuticals Incorporated's price-to-earnings ratio?
Vertex Pharmaceuticals Incorporated (VRTX) reported price-to-earnings ratio of 29.59 for fiscal year 2025, per its SEC filings.
How has Vertex Pharmaceuticals Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, VRTX's price-to-earnings ratio declined at roughly 11.5% per year (compound annual rate), from 237.21 to 29.59.
Where does this data come from?
Figures are computed from Vertex Pharmaceuticals Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.